Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Allogene Therapeutics

General information

Main focus: Allogeneic CAR-T cell therapies

Company stage: Clinical

Diseases: Non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML), renal cell carcinoma (RCC), small cell lung cancer (SCLC)

Genome editing tool: TALEN

Funding stage: Public (NASDAQ:ALLO)

Location: San Francisco, CA, USA



Partners: Cellectis, Servier, Notch Therapeutics, SpringWorks Therapeutics, Pfizer

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Allogene is developing a pipeline ofoff-the-shelf CAR-T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.


HashtagAllogene Therapeutics, Inc.

Company: Allogene Therapeutics
Search CRISPR Medicine